argenx has announced it will advance ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK), to a registrational study in patients with congenital myasthenic syndromes (CMS). The decision follows the analysis of topline data from the Phase Ib study, in which ARGX-119 demonstrated a favourable safety and tolerability profile. “The… Read More
Researchers in Japan have revealed the key underlying mechanisms in muscle atrophy, paving the way towards potential new treatments. While the disuse of muscles is the most frequent catalyst for muscle atrophy, there are several other possible causes, including chronic diseases, injury and exposure to low-gravity… Read More
Israeli researchers have developed a drug that is effective in treating a rare genetic muscle disease. The research team from Ben-Gurion University of the Negev and Soroka Medical Center discovered the severe hereditary muscle disease that develops around the age of 40 years, progressing to complete… Read More
Researchers have identified the genetic links between muscle atrophy and two types of myosin, paving the way for a new disease model for scientific research and potential new treatments. The synergistic action of the muscle proteins myosin and actin enables skeletal muscle movements. The skeletal muscle myosin… Read More
BridgeBio has been granted Fast Track designation United States Food and Drug Administration (FDA) for the investigation of BBP-418 as a treatment option for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i). This is the fifth Fast Track designation for an investigational therapy that BridgeBio has received in 2021. BridgeBio’s LGMD2i investigational therapy… Read More
Scientists at St. Jude Children’s Research Hospital are studying how signals sent from skeletal muscle affect the brain. The team studied fruit flies and brain cell models called organoids, focusing on the signals that muscles send when stressed. They used immunostaining and confocal microscopy on the fruit fly brain and… Read More
